CN112675193A - Composition powder for treating auditory canal diseases and application thereof - Google Patents

Abstract

The invention discloses a composition powder for treating auditory canal diseases and application thereof, wherein the composition comprises the following components by weight per 100 mg: 60-90mg of dried alum, 5-8mg of borneol, 0.15-0.75mg of gentamicin sulfate crystal powder, 0.5-3mg of miconazole nitrate crystal powder, and the balance of auxiliary material talcum powder. The invention adopts a formula combining traditional Chinese medicine and western medicine, has quick curative effect, improves the environment in the auditory canal, simultaneously has quick and effective sterilization of western medicine, can have the effect of simultaneously treating multiple pathogenic infections, has the functions of convergence, dryness, itching relieving, inflammation diminishing and dehumidification, makes the auditory canal of animals comfortable in the treatment process, reduces the uneasy mood of the animals, and is not easy to relapse after medicine withdrawal.

Description

Composition powder for treating auditory canal diseases and application thereof

Technical Field

The invention belongs to the field of medicines, and relates to composition powder for auditory canal diseases and application thereof.

Background

Animal ear canal diseases, such as malassezia infection or mixed infection ear canal diseases, can be manifested as red swelling, pruritus and large amount of earwax secretion after infection, and the ear canal always presents in a moist and greasy state. The environment in the auditory canal of the animal is weak and alkaline, and the weak alkaline environment is more suitable for the growth and reproduction of pathogens, so that the disease is more serious. At this time, the animals can scratch ears repeatedly, and are difficult to endure with pruritus and dysphoria.

The inventor carries out clinical medical work on small animals for more than 15 years, and in the clinical medical work for 15 years, the existing medicines for treating the auditory canal diseases of malassezia infection or mixed infection of dogs and cats are found to be basically in a liquid form or a paste form, have relatively single functions, and are mostly effective only for one type of pathogen.

In addition, the therapeutic products for the auditory canal diseases are basically in liquid dosage forms or paste dosage forms, have relatively single functions, and are mostly only effective for one type of pathogen. Part of compound preparations are pure western medicine preparations, and in clinical medical treatment, treatment products on the market have good sterilization effect, but the humid environment of the auditory canal is not improved well after the treatment, the environment in the auditory canal cannot be improved fundamentally, the auditory canal infection is easy to relapse after the treatment is finished for a period of time, and the treatment effect is not ideal enough due to the drug resistance generated along with the extension of the treatment period. On the other hand, repeated attacks of ear canal diseases cause physical discomfort to the animals, and the breeder also takes a lot of time in the treatment process. Therefore, the inventor carries out research and development work in actual clinic to create a novel compound preparation for treating the ear canal infection of the small animals.

Disclosure of Invention

The invention aims to provide composition powder for treating auditory canal diseases and application thereof, which can improve and treat auditory canal diseases of animals such as malassezia infection or mixed infection, improve the pH value of the environment in the auditory canals of the animals, inhibit the growth of pathogens, destroy the living environment of the pathogens, make the auditory canals of the animals comfortable and reduce the uneasy mood of the animals.

In order to achieve the purpose, the technical scheme of the invention is as follows:

in one aspect, the present invention provides a powder composition for treating ear canal diseases, wherein the composition comprises the following components per 100 mg: 60-90mg of dried alum, 5-8mg of borneol, 0.15-0.75mg of gentamicin sulfate crystal powder, 0.5-3mg of miconazole nitrate crystal powder, and the balance of auxiliary material talcum powder.

Further, the gentamicin sulfate crystal powder is preferably 0.45-0.75mg, and the miconazole nitrate crystal powder is preferably 2-3 mg.

Furthermore, the composition powder also comprises 0.15-1mg of ivermectin crystal powder. The ivermectin crystal powder is preferably 0.45-1 mg.

In another aspect, the invention also provides the application of the composition powder in preparing antibacterial drugs.

Furthermore, the invention also provides application of the composition powder in preparing antifungal and antibacterial medicines.

Furthermore, the invention also provides application of the composition powder in preparation of medicaments for resisting malassezia and gram-positive bacteria.

Furthermore, the invention also provides application of the composition powder in preparing medicines for resisting malassezia, staphylococcus and streptococcus.

In another aspect, the invention also provides application of the composition powder in preparation of antibacterial and anti-earmite medicines.

Furthermore, the invention also provides application of the composition powder in preparing antifungal, antibacterial and anti-otomite medicines.

Furthermore, the invention also provides application of the composition powder in preparation of medicaments for resisting malassezia, gram-positive bacteria and earmites.

Furthermore, the invention also provides application of the composition powder in preparing medicines for resisting malassezia, staphylococcus, streptococcus and otomite.

Theoretical explanation of the formula:

the dried alum is a traditional Chinese medicine component, mainly contains anhydrous aluminum potassium sulfate, has the functions of convergence, drying and dehumidification, can be used on the surface of the mucous membrane of the auditory canal, can contract wax glands and reduce cerumen secretion, thereby improving the environment in the auditory canal. The normal dry powder state is neutral pH value, and can gradually change into weak acid environment with pH value of 6.5-6.8 in the process of absorbing water in auditory canal, thereby inhibiting growth of pathogenic bacteria, making auditory canal of animal comfortable, and reducing emotional feeling of animal.

The borneol is called borneol incense, is a traditional Chinese medicine component, has the functions of astringing, resisting inflammation and relieving itching, eliminating swelling of mucous membrane and repairing epidermis, and can relieve itching and inflammation, eliminate swelling of the auditory canal and promote the growth and healing of the mucous membrane of the auditory canal when being applied to the surface of the mucous membrane of the auditory canal. Meanwhile, the product has the effects of astringing dryness and improving the environment of the auditory canal.

The gentamicin sulfate is a sulfate form of gentamicin, belongs to aminoglycoside antibiotics, and has an antibacterial mechanism of combining with 30S subunit on mycoprotein, thereby blocking the synthesis of mycoprotein and achieving the antibacterial effect. Has good effect on various gram-negative bacteria and gram-positive bacteria. Gentamicin sulfate has great nephrotoxicity and ototoxicity when being taken orally or injected, but the safety degree of the application of the epidermal mucosa is extremely high.

Miconazole nitrate is the nitrate form of miconazole. Miconazole is an efficient, safe, broad-spectrum antifungal agent, and has effects on pathogenic fungi. The mechanism is to inhibit sterol synthesis of fungal cell membrane, influence cell membrane permeability, inhibit fungal growth and cause death. Meanwhile, the miconazole also has antibacterial effect on staphylococcus and streptococcus, gram-positive coccus and anthrax, and the like.

Ivermectin is a broad-spectrum, high-efficiency and low-toxicity anti-parasitic drug, and has good expelling and killing effects on nematodes and arthropods (especially mites). The mechanism of action is that the release of inhibitory transmitter gamma-aminobutyric acid (GABA) of the polypide is increased, a chloride ion channel controlled by glutamic acid is opened, the permeability of nerve membrane polychloride is enhanced, the transmission of nerve signals of the polypide is blocked, and finally the polypide is paralyzed and dies.

The invention has the advantages that:

the composition powder adopts a formula combining traditional Chinese medicine and western medicine, has quick curative effect, improves the environment in the auditory canal, simultaneously has quick and effective sterilization of western medicine, can simultaneously treat multiple pathogenic infections, has the functions of convergence, dryness, itching relieving, inflammation diminishing and dehumidification, makes the auditory canal of animals comfortable in the treatment process, reduces the uneasy mood of the animals, and is not easy to relapse after medicine withdrawal.

The ear cleaning powder is powder, is different from the existing liquid or ointment, is a micropowder, can be used for cleaning by normal secretion of the auditory canal after entering the auditory canal, and has the characteristics of easy cleaning and little residue, so the ear cleaning powder has extremely high safety and no toxic or side effect, and is the characteristic that other animal ear medicine products in the existing market do not have.

Detailed Description

The treatment principle of the composition powder for treating the auditory canal diseases of the invention is as follows:

clinically, the most common problem in the ear canal of animals is infection with staphylococci, malassezia and otitis mites, usually single or multiple infections, mostly associated with moist ear canals;

after the infection, the auditory canal of the animal shows red swelling, pruritus and a large amount of cerumen secretion, and the auditory canal always shows a moist and greasy state. The environment in the auditory canal of the animal is weak and alkaline, and the weak alkaline environment is more suitable for the growth and reproduction of pathogens, so that the disease is more serious. At the moment, the animals can scratch ears repeatedly, and are difficult to endure and dysphoria;

after the composition powder is used, the dried alum and borneol can quickly absorb water in the auditory canal, so that the auditory canal becomes dry. After absorbing water, the dried alum gradually changes the environment in the auditory canal into weak acidity, which is not suitable for the reproduction and growth of pathogens, thereby achieving the purpose of inhibiting the growth of pathogens. The borneol can eliminate and reduce swelling of the mucous membrane of the auditory canal, reduce pruritus, inhibit the secretion of wax glands, further destroy the living environment of pathogens, make the auditory canal of an animal comfortable and reduce the emotional uneasiness of the animal. The gentamicin sulfate and the miconazole can quickly kill staphylococcus and malassezia in ears, and the pathogeny is fundamentally solved. Ivermectin also achieves a quick kill effect against otitis mite infected animals.

The composition powder is prepared by mixing the components, and grinding the mixture at high speed to prepare a micro powder formulation.

Since ivermectin is effective only against mites and not against bacterial fungi, the powder of the pharmaceutical composition of the present invention was prepared in three examples and the three examples were divided into three groups for experiments. In the first embodiment, experiments of different proportions of gentamicin sulfate and miconazole are carried out, in the second embodiment, experiments of proportions of ivermectin are carried out, and in the third embodiment, experiments of different proportions of dried alum and borneol are carried out.

In addition, the fourth example is also carried out, the similar products are used as the control experiments, and the otoxin of Fa-national Wenlong and the otoxin of China Sheng Pet are selected as the drugs for the control experiments.

The various examples are as follows:

example one, 12 experimental groups of pharmaceutical composition powders were prepared and numbered, each experimental group being 100mg, the 12 experimental groups being specifically as follows:

code No. a 1: 80mg of dried alum, 8mg of borneol, 0.15mg of gentamicin sulfate and 0.5mg of miconazole, and the balance of talcum powder;

code No. a 2: 80mg of dried alum, 8mg of borneol, 0.45mg of gentamicin sulfate and 0.5mg of miconazole, and the balance of talcum powder;

code No. a 3: 80mg of dried alum, 8mg of borneol, 0.75mg of gentamicin sulfate and 0.5mg of miconazole, and the balance of talcum powder;

number B1: 80mg of dried alum, 8mg of borneol, 0.15mg of gentamicin sulfate and 1mg of miconazole, and the balance of talcum powder;

number B2: 80mg of dried alum, 8mg of borneol, 0.45mg of gentamicin sulfate and 1mg of miconazole, and the balance of talcum powder;

number B3: 80mg of dried alum, 8mg of borneol, 0.75mg of gentamicin sulfate and 1mg of miconazole, and the balance of talcum powder;

number C1: 80mg of dried alum, 8mg of borneol, 0.15mg of gentamicin sulfate and 2mg of miconazole, and the balance of talcum powder;

number C2: 80mg of dried alum, 8mg of borneol, 0.45mg of gentamicin sulfate and 2mg of miconazole, and the balance of talcum powder;

number C3: 80mg of dried alum, 8mg of borneol, 0.75mg of gentamicin sulfate and 2mg of miconazole, and the balance of talcum powder;

number D1: 80mg of dried alum, 8mg of borneol, 0.15mg of gentamicin sulfate and 3mg of miconazole, and the balance of talcum powder;

number D2: 80mg of dried alum, 8mg of borneol, 0.45mg of gentamicin sulfate and 3mg of miconazole, and the balance of talcum powder;

number D3: 80mg of dried alum, 8mg of borneol, 0.75mg of gentamicin sulfate, 3mg of miconazole and the balance of talcum powder.

Example two, the pharmaceutical composition powders of 7 experimental groups were prepared and numbered, wherein each experimental group is 100mg, and the 7 experimental groups are specifically as follows:

a: 80mg of dried alum, 8mg of borneol, 0.45mg of gentamicin sulfate, 1mg of miconazole and 0.15mg of ivermectin, and the balance of talcum powder;

b: 80mg of dried alum, 8mg of borneol, 0.45mg of gentamicin sulfate, 1mg of miconazole and 0.3mg of ivermectin, and the balance of talcum powder is complemented;

c: 80mg of dried alum, 8mg of borneol, 0.45mg of gentamicin sulfate, 1mg of miconazole and 0.45mg of ivermectin, and the balance of talcum powder;

d: 80mg of dried alum, 8mg of borneol, 0.45mg of gentamicin sulfate, 1mg of miconazole and 0.6mg of ivermectin, and the balance of talcum powder;

e: 80mg of dried alum, 8mg of borneol, 0.45mg of gentamicin sulfate, 1mg of miconazole and 0.75mg of ivermectin, and the balance of talcum powder;

f: 80mg of dried alum, 8mg of borneol, 0.45mg of gentamicin sulfate, 1mg of miconazole and 0.9mg of ivermectin, and the balance of talcum powder;

g: 80mg of dried alum, 8mg of borneol, 0.45mg of gentamicin sulfate, 1mg of miconazole and 1mg of ivermectin, and the balance of talcum powder is complemented.

Example three, 16 experimental groups of pharmaceutical composition powders were prepared and numbered, each experimental group being 100mg, 7 experimental groups being specifically as follows:

number E1: 0.45mg of gentamicin sulfate, 1mg of miconazole, 60mg of dried alum and 5mg of borneol, wherein the rest is complemented by talcum powder;

number E2: 0.45mg of gentamicin sulfate, 1mg of miconazole, 60mg of dried alum and 6mg of borneol, wherein the rest is complemented by talcum powder;

number E3: 0.45mg of gentamicin sulfate, 1mg of miconazole, 60mg of dried alum and 7mg of borneol, wherein the rest is complemented by talcum powder;

number E4: 0.45mg of gentamicin sulfate, 1mg of miconazole, 60mg of dried alum and 8mg of borneol, wherein the rest is complemented by talcum powder;

number F1: 0.45mg of gentamicin sulfate, 1mg of miconazole, 70mg of dried alum and 5mg of borneol, wherein the rest is complemented by talcum powder;

number F2: 0.45mg of gentamicin sulfate, 1mg of miconazole, 70mg of dried alum and 6mg of borneol, wherein the rest is complemented by talcum powder;

number F3: 0.45mg of gentamicin sulfate, 1mg of miconazole, 70mg of dried alum and 7mg of borneol, wherein the rest is complemented by talcum powder;

number F4: 0.45mg of gentamicin sulfate, 1mg of miconazole, 70mg of dried alum and 8mg of borneol, wherein the rest is complemented by talcum powder;

number G1: 0.45mg of gentamicin sulfate, 1mg of miconazole, 80mg of dried alum and 5mg of borneol, wherein the rest is complemented by talcum powder;

number G2: 0.45mg of gentamicin sulfate, 1mg of miconazole, 80mg of dried alum and 6mg of borneol, wherein the rest is complemented by talcum powder;

number G3: 0.45mg of gentamicin sulfate, 1mg of miconazole, 80mg of dried alum and 7mg of borneol, wherein the rest is complemented by talcum powder;

number G4: 0.45mg of gentamicin sulfate, 1mg of miconazole, 80mg of dried alum and 8mg of borneol, wherein the rest is complemented by talcum powder;

number H1: 0.45mg of gentamicin sulfate, 1mg of miconazole, 90mg of dried alum and 5mg of borneol, wherein the rest is complemented by talcum powder;

number H2: 0.45mg of gentamicin sulfate, 1mg of miconazole, 90mg of dried alum and 6mg of borneol, wherein the rest is complemented by talcum powder;

number H3: 0.45mg of gentamicin sulfate, 1mg of miconazole, 90mg of dried alum and 7mg of borneol, wherein the rest is complemented by talcum powder;

number H4: 0.45mg of gentamicin sulfate, 1mg of miconazole, 90mg of dried alum and 8mg of borneol, and the balance of talcum powder is complemented.

Experiment of example one:

the experimental animals were selected from dogs and cats with healthy ear canals, and 5 dogs and 5 cats were divided into one group.

All experimental animals artificially produced ear canal infections and were classified into the following categories according to the type of infection artificially produced:

(1)1001 category: artificially manufacturing malassezia infection of the auditory canals of experimental animals. After the experimental animal has obvious infection symptoms, the secretion of the auditory canal is taken to be subjected to Rajzier staining, the auditory canal is placed under a microscope, the quantity of malassezia under each microscope field is observed and recorded by using an oil lens under 1000 times magnification until the sum of the counts under 3 consecutive microscope fields reaches 100, and the preparation of the experimental animal is completed.

(2)1002, category: artificially manufacturing staphylococcus infection in auditory canals of experimental animals. After the experimental animal has obvious infection symptoms, the secretion of the auditory canal is taken to be subjected to Rajji's staining, the auditory canal is placed under a microscope, the quantity of staphylococcus under each microscope field is observed and recorded by using an oil lens under 1000 times magnification, and the experimental animal is ready to finish the preparation until the counting sum under 3 consecutive microscope fields reaches 500.

(3) Class 1003: artificially manufacturing a mixed infection of malassezia and staphylococcus in the auditory canal of an experimental animal. After the experimental animal has obvious infection symptoms, the auditory meatus secretion is taken to be subjected to Rajzier staining, the auditory meatus secretion is placed under a microscope, the quantity of the malassezia and the staphylococcus under each microscope field is observed and recorded by using an oil lens under 1000 times magnification until the sum of the counts under 3 consecutive microscope fields reaches 500, and the preparation of the experimental animal is completed. In this category, Malassezia and Staphylococcus were counted and no distinction was made.

Wherein the number of colonies from 10 animals per group was averaged.

(II) distributing three types of experimental animals for the pharmaceutical composition powder with 12 experimental group numbers in the first example, which are as follows:

1001

A1

A2

A3

B1

B2

B3

C1

C2

C3

D1

D2

D3

1002

A1

A2

A3

B1

B2

B3

C1

C2

C3

D1

D2

D3

1003

A1

A2

A3

B1

B2

B3

C1

C2

C3

D1

D2

D3

and (III) cleaning the auditory canal once a day by using ear cleaning liquid special for dogs and cats, wiping the auditory canal clean, and then putting 50mg of medicinal powder with the corresponding number into the auditory canal, wherein the medicinal powder cannot be cleaned out after putting. This operation was repeated again the next day.

And (IV) before cleaning the auditory canal on day 1, taking auditory canal secretion for Raji staining microscopy, and determining that the experimental object meets the experimental requirements again.

And (V) before cleaning auditory canals on the 4 th day, the 7 th day, the 10 th day, the 13 th day and the 16 th day, performing Ray-Ji's stauroscopy on auditory canal secretions, and recording the counting sum of pathogenic bacteria under 3 continuous microscopic fields according to different categories.

Sixthly, calculating the antibacterial efficiency of each group according to the record of experimental data;

(1) summary of 1001 categories antimicrobial efficacy:

(2)1002 category antibacterial efficiency summary table:

(3)1003 type antibacterial efficiency summary table:

analysis and summary of experimental results:

(1) the group of Malassezia 1001 is,

when the content of the miconazole is 0.5mg, the bacteriostatic effect reaches 50% in 7 days, more than 70% in 10 days and more than 90% in 13 days;

when the content of the miconazole is 1mg, the bacteriostatic effect reaches 70% in 7 days, 90% in 10 days and 100% in 13 days;

when the content of the miconazole is 2mg, the bacteriostatic effect reaches 65% in 4 days, 90% in 7 days and 100% in 10 days;

when the content of the miconazole is 3mg, the bacteriostatic effect reaches 70% in 4 days, 90% in 7 days and 100% in 10 days;

experiments show that when the content of the miconazole is within the range of 0.5-3mg, the malassezia inhibition effect can reach more than 90% after the miconazole is continuously used for 13 days, and the concentration range is proved to have good bacteriostatic effect.

(2) The group of class 1002 staphylococci is,

when the content of gentamicin sulfate is 0.15mg, the bacteriostatic effect reaches 20% in 4 days, 60% in 7 days, 80% in 10 days and more than 95% in 13 days;

when the content of gentamicin sulfate is 0.45mg, the bacteriostatic effect reaches 40% in 4 days, 80% in 7 days, 97% in 10 days and 100% in 13 days;

when the content of gentamicin sulfate is 0.75mg, the bacteriostatic effect reaches more than 45% in 4 days, more than 87% in 7 days and 100% in 10 days;

experiments show that when the gentamicin sulfate content is within the range of 0.15mg-0.75mg, the staphylococcus inhibiting effect can reach 100% after the gentamicin sulfate is continuously used for 13 days, and the concentration range is proved to have a good antibacterial effect.

(3) Group 1003 mixed by malassezia and staphylococcus,

the experimental data show that the bacteriostatic effect of all experimental groups in 4 days is 30% at least and 60% at most, the bacteriostatic effect of all experimental groups in 7 days is 83% at least and 95% at most, and the bacteriostatic effect of all experimental groups in 10 days is more than 99%.

Experimental data prove that the bacteriostatic rate reaches 99% in 10 days and the bacteriostatic effect is excellent in the ranges of 0.15-0.75mg (per 100 mg) of gentamicin sulfate and 0.5-3mg (per 100 mg) of miconazole.

Experiment of example two:

experimental animals dogs and cats with healthy ear canals were selected, and 3 dogs and 7 cats were divided into one group.

All experimental animals artificially infected with tsutsugamushi in the auditory canal. After the experimental animal has obvious infection symptoms, taking the secretion of the auditory canal for transparent tabletting, placing under a microscope, observing and recording the number of the tsutsugamushi mites under each microscope visual field by using a low power lens for 40 times magnification until the sum of the counts under 3 continuous microscope visual fields reaches 10, and finishing the preparation of the experimental animal.

(iii) pharmaceutical composition powders of 7 experimental groups of example two, each group was assigned to one experimental animal.

The ear cleaning liquid is used for cleaning the auditory meatus once a day, after the auditory meatus is wiped clean, 50mg of medicinal powder of a corresponding group is put into the auditory meatus, and the medicinal powder cannot be cleaned out after the medicinal powder is put into the auditory meatus. This operation was repeated again the next day.

And (IV) before cleaning the auditory canal on day 1, taking auditory canal secretion for performing transparent method tabletting microscopic examination, and determining that the experimental object meets the experimental requirements again.

And (V) performing transparent press-lens examination on the secretion of the auditory canal before cleaning the auditory canal on the 4 th, 7 th, 10 th, 13 th and 16 th days, and recording the sum of the counts of the trombicula chigger under 3 continuous microscopic fields.

And (VI) stopping the application of the pesticide to each experimental group from the 17 th day according to the breeding characteristics and the breeding cycle of the auricles, performing transparent tabletting microscopic examination on the secretion of the auditory canals on the 23 rd day and the 30 th day, and recording the sum of the counts of the auricles aurantiaca under continuous 3 microscopic fields.

And (seventhly), calculating the mite removing efficiency of each group according to the record of experimental data.

Experimental data prove that 100% of ivermectin can be removed in 10 days when the ivermectin content is between 0.15 and 1mg, the effect is excellent, and the ivermectin can be completely cured without repetition after stopping administration.

Experiment of example three:

experimental animals dogs and cats were selected for healthy ear canals. Groups of 5 dogs and 5 cats were divided.

All experimental animals artificially produced mixed infections of malassezia spp and staphylococcus spp. After the experimental animal has obvious infection symptoms, the auditory meatus secretion is subjected to Rajjel staining and placed under a microscope, the number of malassezia and staphylococcus under each microscope field is observed and recorded by a 1000-time oil microscope of an optical microscope, the data of 10 animals in each group is averaged until the sum of the counts under 3 continuous microscope fields reaches 500, and the preparation of the experimental animal is completed. The total number of Malassezia and Staphylococcus was counted and no distinction was made.

And (II) cleaning auditory canals of dogs and cats by using the ear cleaning liquid, and then throwing the medicinal powder according to various proportions into the auditory canals of experimental animals once a day, wherein the amount of the medicinal powder in the ears is about 50mg each time. Auditory canal endocrine staining microscopy was performed every three days with experimental data as follows:

summary of the analysis of the Experimental results

The experimental data show that the bacteriostatic effect of all experimental groups reaches more than 43% in 4 days, more than 84% in 7 days and more than 98% in 10 days.

Experimental data prove that the bacterial inhibition rate reaches more than 98% in 10 days and the bacterial inhibition effect is excellent within the ranges of 60-90mg (per 100 mg) of dried alum and 5-8mg (per 100 mg) of borneol.

EXAMPLE four control experiment of similar products

The drug for control experiments was selected as "Erfuning" of Fangwei Longu and "Ershu" of Sheng Pet of China. Each group of 10 experimental animals, 5 animals each for dogs and cats, were artificially infected with the mixed antrum auris of malassezia and staphylococcus.

After the ear cleaning liquid is used for cleaning auditory canals of dogs and cats, the medicine is put into the auditory canals of experimental animals according to the instruction of medicine use, and the operation is carried out once a day. Auditory canal endocrine staining microscopy was performed every three days.

The experimental data are summarized, the total number of the malassezia and the staphylococcus is 500 under the continuous 3 microscope visual fields observed by an oil microscope with 1000 times of an optical microscope, the standard is 100 percent, and the data of 10 animals in each group are averaged.

Otofurazolin control group

Ear comfort control group

Wherein, 1, the data in the two comparison group tables are the comprehensive counting of staphylococcus and malassezia under 3 oil-scope visual fields; 2. the average percentage is calculated as the average divided by 500; 3. the antimicrobial efficiency was calculated by subtracting the percent of the mean from 100%.

The summary of antimicrobial efficacy is as follows:

analysis and summary of experimental results:

experimental data show that the control group of the otofurazolin has 15% of bacteriostatic effect in 4 days, 50% of bacteriostatic effect in 7 days, 78% of bacteriostatic effect in 10 days and more than 95% of bacteriostatic effect in 13 days. The anti-bacterial effect of the ear comfort control group reaches 13% in 4 days, 45% in 7 days, 70% in 10 days, 82% in 13 days and 74% in 16 days.

The experimental data for the four examples finally show that:

the imported medicine otofurazolin has 78 percent of bacteriostatic effect in 10 days, 96.4 percent of bacteriostatic effect in 13 days and good bacteriostatic effect; however, on the 25 th day after the experiment, the auditory canal infection of the experimental animals of the auricular skin panacea group part recurs, and the auricular skin panacea contains the glucocorticoid triamcinolone acetonide, so that the hormone is considered to possibly cause the immunosuppression of the auditory canal mucosa, the normal immune barrier function of the auditory canal mucosa is lost, and the secondary infection is caused;

the domestic medicine Ershu component is florfenicol, the 13-day antibacterial effect is 82%, the 16-day antibacterial effect is reduced to 74%, the antibacterial effect is not ideal, the main reason is that the Ershu can only inhibit staphylococcus, the Eraserod is ineffective, and the antibacterial effect does not increase and inversely decrease along with continuous proliferation of the Eraserod after 13 days;

the invention has the bacteriostatic effect of more than 90 percent in 10 days (only 78 percent of otofural), and the bacteriostatic effect of 100 percent in 13 days (only 96 percent of otofural). The invention has obviously shorter effective time than that of otofurazolin, and can control and eliminate the ear infection more quickly and effectively. The otofurazolin comprises the following components of all western medicines: neomycin sulfate, nystatin, permethrin and triamcinolone acetonide (namely glucocorticoid), wherein the triamcinolone acetonide has certain influence on endocrine metabolism and immune system. The invention has stronger antibacterial effect than otofurazolin, does not contain any hormone, has no influence on endocrine metabolism and immune system, and has higher safety factor.

Therefore, the invention has good effect on treating mixed ear canal infection of animals, has very excellent bacteriostatic effect, and has bacteriostatic ability superior to similar products.

Example one, example two and example three experimental animal side reaction statistics: all experimental animals of the invention do not find drug side reaction and anaphylactic reaction, and the auditory canal mucous membrane of the animal gradually recovers to be normal along with the progress of the experiment, and the clinical pathological characteristics basically disappear. The invention proves that the invention has high safety and no toxic or side effect when being used strictly in the auditory canal during the treatment of auditory canal diseases.

Claims (10)

1. A powder composition for use in the treatment of ear canal disease, characterized by:

the content of each component in the composition is calculated by every 100mg as follows: 60-90mg of dried alum, 5-8mg of borneol, 0.15-0.75mg of gentamicin sulfate crystal powder, 0.5-3mg of miconazole nitrate crystal powder, and the balance of auxiliary material talcum powder.

2. The composition powder of claim 1, wherein:

the content of gentamicin sulfate crystal powder is 0.45-0.75mg, and the content of miconazole nitrate crystal powder is 2-3 mg.

3. The composition powder as claimed in claim 1 or 2, wherein: also comprises 0.15-1mg of ivermectin crystal powder.

4. Composition powder according to claim 3, characterized in that: the content of the ivermectin crystal powder is 0.45-1 mg.

5. Use of a powder composition according to claim 1 or 2 for the preparation of an antifungal and antibacterial medicament.

6. Use of a powder composition according to claim 1 or 2 for the preparation of a medicament against malassezia and gram-positive bacteria.

7. Use of a powder composition according to claim 1 or 2 for the manufacture of a medicament against malassezia, staphylococcus and streptococcus.

8. Use of the composition powder of claim 3 or 4 for the preparation of an antibacterial and anti-otomite medicament.

9. The composition of claim 3 or 4, wherein the composition is in the form of powder, and the powder is used for preparing antifungal, antibacterial and anti-otomite medicines.

10. Use of a powder composition according to claim 3 or 4 for the manufacture of a medicament against malassezia, staphylococcus, streptococcus and otitis mite.